If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> ISSN 2054-619X Vol 6.1 • December 2018 • europeanmedical-journal.com<br /> INSIDE<br /> Review of<br /> ESMO 2018<br /> Munich, Germany<br /> Contents<br /> EDITORIAL BOARD 4<br /> WELCOME 7<br /> FOREWORD 9<br /> 01 CONGRESS REVIEW<br /> Review of ESMO 2018, held in Munich, Germany, 19th–23rd October 2018 12<br /> BUYER'S GUIDE 36<br /> 02 INTERVIEW WITH EMJ ONCOLOGY EDITORIAL BOARD'S<br /> Dr Fausto Roila <a title="EMJ Oncology 6.1 2018 page 1" href="http://viewer.zmags.com/publication/506173e7?page=1"> ONCOLOGY ISSN 2054-619X </a> <a title="EMJ Oncology 6.1 2018 page 2" href="http://viewer.zmags.com/publication/506173e7?page=2"> Contents EDITORIAL BOARD </a> <a title="EMJ Oncology 6.1 2018 page 3" href="http://viewer.zmags.com/publication/506173e7?page=3"> "A very warm welcome to EMJ Oncology 6.1, which i</a> <a title="EMJ Oncology 6.1 2018 page 4" href="http://viewer.zmags.com/publication/506173e7?page=4"> Editorial Board Editor-in-Chief Dr Ahmad Awada E</a> <a title="EMJ Oncology 6.1 2018 page 5" href="http://viewer.zmags.com/publication/506173e7?page=5"> Aims and Scope The European Medical Journal (EMJ)</a> <a title="EMJ Oncology 6.1 2018 page 6" href="http://viewer.zmags.com/publication/506173e7?page=6"> EMJ Oncol. Chief Executive Officer Spencer Gore S</a> <a title="EMJ Oncology 6.1 2018 page 7" href="http://viewer.zmags.com/publication/506173e7?page=7"> Welcome A very warm welcome to EMJ Oncology 6.1, </a> <a title="EMJ Oncology 6.1 2018 page 8" href="http://viewer.zmags.com/publication/506173e7?page=8"> </a> <a title="EMJ Oncology 6.1 2018 page 9" href="http://viewer.zmags.com/publication/506173e7?page=9"> Foreword In this edition of EMJ Oncology, four pa</a> <a title="EMJ Oncology 6.1 2018 page 10" href="http://viewer.zmags.com/publication/506173e7?page=10"> Available now.</a> <a title="EMJ Oncology 6.1 2018 page 11" href="http://viewer.zmags.com/publication/506173e7?page=11"> Included inside: Congress Review + Review of E</a> <a title="EMJ Oncology 6.1 2018 page 12" href="http://viewer.zmags.com/publication/506173e7?page=12"> </a> <a title="EMJ Oncology 6.1 2018 page 13" href="http://viewer.zmags.com/publication/506173e7?page=13"> Congress Review Review of the European</a> <a title="EMJ Oncology 6.1 2018 page 14" href="http://viewer.zmags.com/publication/506173e7?page=14"> During the next 4 days, a myriad of scientific ses</a> <a title="EMJ Oncology 6.1 2018 page 15" href="http://viewer.zmags.com/publication/506173e7?page=15"> Short-Course Trastuzumab Proposals for Treatment </a> <a title="EMJ Oncology 6.1 2018 page 16" href="http://viewer.zmags.com/publication/506173e7?page=16"> the clinical effectiveness results demonstrating </a> <a title="EMJ Oncology 6.1 2018 page 17" href="http://viewer.zmags.com/publication/506173e7?page=17"> Financial Issues Impact Psychological Cancer Burd</a> <a title="EMJ Oncology 6.1 2018 page 18" href="http://viewer.zmags.com/publication/506173e7?page=18"> Adherence to Cancer Screening: EDIFICE Results “I</a> <a title="EMJ Oncology 6.1 2018 page 19" href="http://viewer.zmags.com/publication/506173e7?page=19"> An exercise survey was completed by patients at </a> <a title="EMJ Oncology 6.1 2018 page 20" href="http://viewer.zmags.com/publication/506173e7?page=20"> The researchers found that the desire of in</a> <a title="EMJ Oncology 6.1 2018 page 21" href="http://viewer.zmags.com/publication/506173e7?page=21"> Immune Checkpoint Inhibitors Effective in Mismatc</a> <a title="EMJ Oncology 6.1 2018 page 22" href="http://viewer.zmags.com/publication/506173e7?page=22"> TNB cancers do not express oestrogen or HER</a> <a title="EMJ Oncology 6.1 2018 page 23" href="http://viewer.zmags.com/publication/506173e7?page=23"> life; there are no paediatric trials for this dis</a> <a title="EMJ Oncology 6.1 2018 page 24" href="http://viewer.zmags.com/publication/506173e7?page=24"> Unlike previous reports, the latest CheckMate-142</a> <a title="EMJ Oncology 6.1 2018 page 25" href="http://viewer.zmags.com/publication/506173e7?page=25"> an increase in overall survival of 6.9 months (me</a> <a title="EMJ Oncology 6.1 2018 page 26" href="http://viewer.zmags.com/publication/506173e7?page=26"> After the first year, results showed that 16.0% (n</a> <a title="EMJ Oncology 6.1 2018 page 27" href="http://viewer.zmags.com/publication/506173e7?page=27"> PFS was 13.8 and 8.4 months, respectively (</a> <a title="EMJ Oncology 6.1 2018 page 28" href="http://viewer.zmags.com/publication/506173e7?page=28"> Cancer Drug Reimbursement Approval Time Varies Ac</a> <a title="EMJ Oncology 6.1 2018 page 29" href="http://viewer.zmags.com/publication/506173e7?page=29"> New ESMO Designated Centres of Integrated Oncolog</a> <a title="EMJ Oncology 6.1 2018 page 30" href="http://viewer.zmags.com/publication/506173e7?page=30"> to the numerous successful breast cance</a> <a title="EMJ Oncology 6.1 2018 page 31" href="http://viewer.zmags.com/publication/506173e7?page=31"> “It is so encouraging to see how precision</a> <a title="EMJ Oncology 6.1 2018 page 32" href="http://viewer.zmags.com/publication/506173e7?page=32"> Congress Feature Summary of the ESMO 20</a> <a title="EMJ Oncology 6.1 2018 page 33" href="http://viewer.zmags.com/publication/506173e7?page=33"> analysis in 521 randomised patients with a </a> <a title="EMJ Oncology 6.1 2018 page 34" href="http://viewer.zmags.com/publication/506173e7?page=34"> Reflecting on the ever-increasing role o</a> <a title="EMJ Oncology 6.1 2018 page 35" href="http://viewer.zmags.com/publication/506173e7?page=35"> Next were new insights into the treatment o</a> <a title="EMJ Oncology 6.1 2018 page 36" href="http://viewer.zmags.com/publication/506173e7?page=36"> Buyer's Guide > 10X GENOMICS > ABBVIE, INC. > ACC</a> <a title="EMJ Oncology 6.1 2018 page 37" href="http://viewer.zmags.com/publication/506173e7?page=37"> > JANSSEN PHARMACEUTICAL, INC. > LOXO ONCOLOG</a> <a title="EMJ Oncology 6.1 2018 page 38" href="http://viewer.zmags.com/publication/506173e7?page=38"> Interview In this edition's Editorial Board </a> <a title="EMJ Oncology 6.1 2018 page 39" href="http://viewer.zmags.com/publication/506173e7?page=39"> cancer patients, I spend my working days at the f</a> <a title="EMJ Oncology 6.1 2018 page 40" href="http://viewer.zmags.com/publication/506173e7?page=40"> this problem. Therefore, CIPOMO is considered imp</a> <a title="EMJ Oncology 6.1 2018 page 41" href="http://viewer.zmags.com/publication/506173e7?page=41"> The answer to this question is not simple.</a> <a title="EMJ Oncology 6.1 2018 page 42" href="http://viewer.zmags.com/publication/506173e7?page=42"> The Right Therapy Starts with the Right Test: No</a> <a title="EMJ Oncology 6.1 2018 page 43" href="http://viewer.zmags.com/publication/506173e7?page=43"> Testing Turnaround Times  Complete biomarker resu</a> <a title="EMJ Oncology 6.1 2018 page 44" href="http://viewer.zmags.com/publication/506173e7?page=44"> Furthermore, in 46–80%  of patient cases, the sta</a> <a title="EMJ Oncology 6.1 2018 page 45" href="http://viewer.zmags.com/publication/506173e7?page=45"> indicator of the importance of investigating</a> <a title="EMJ Oncology 6.1 2018 page 46" href="http://viewer.zmags.com/publication/506173e7?page=46"> OVARIAN AND BREAST CANCERS: THE NEED FOR BRCA TES</a> <a title="EMJ Oncology 6.1 2018 page 47" href="http://viewer.zmags.com/publication/506173e7?page=47"> trial28 suggesting that changes in plasma levels </a> <a title="EMJ Oncology 6.1 2018 page 48" href="http://viewer.zmags.com/publication/506173e7?page=48"> What was once a vision for improved cancer key </a> <a title="EMJ Oncology 6.1 2018 page 49" href="http://viewer.zmags.com/publication/506173e7?page=49"> Share your knowledge with the w</a> <a title="EMJ Oncology 6.1 2018 page 50" href="http://viewer.zmags.com/publication/506173e7?page=50"> Prediction with Precision: Does TAILORx Mak</a> <a title="EMJ Oncology 6.1 2018 page 51" href="http://viewer.zmags.com/publication/506173e7?page=51"> brought into the perspective of clinical practice</a> <a title="EMJ Oncology 6.1 2018 page 52" href="http://viewer.zmags.com/publication/506173e7?page=52"> Table 1: Discordance between the Oncotype DX® Bre</a> <a title="EMJ Oncology 6.1 2018 page 53" href="http://viewer.zmags.com/publication/506173e7?page=53"> the wide CI for patients with RS 10–25 could not </a> <a title="EMJ Oncology 6.1 2018 page 54" href="http://viewer.zmags.com/publication/506173e7?page=54"> Altogether, the TAILORx primary analysis </a> <a title="EMJ Oncology 6.1 2018 page 55" href="http://viewer.zmags.com/publication/506173e7?page=55"> Additionally, as discussed, the tests have been s</a> <a title="EMJ Oncology 6.1 2018 page 56" href="http://viewer.zmags.com/publication/506173e7?page=56"> RS 18–30, and substantial with RS 31–100. F</a> <a title="EMJ Oncology 6.1 2018 page 57" href="http://viewer.zmags.com/publication/506173e7?page=57"> 19. Sparano JA, Paik S. Development of </a> <a title="EMJ Oncology 6.1 2018 page 58" href="http://viewer.zmags.com/publication/506173e7?page=58"> Genomic Profiling Clinical Trials in Cancer of Un</a> <a title="EMJ Oncology 6.1 2018 page 59" href="http://viewer.zmags.com/publication/506173e7?page=59"> The second approach is to identify genomic aberra</a> <a title="EMJ Oncology 6.1 2018 page 60" href="http://viewer.zmags.com/publication/506173e7?page=60"> Favourable subsets include men with poorly d</a> <a title="EMJ Oncology 6.1 2018 page 61" href="http://viewer.zmags.com/publication/506173e7?page=61"> The second approach uses genomic profiling to find </a> <a title="EMJ Oncology 6.1 2018 page 62" href="http://viewer.zmags.com/publication/506173e7?page=62"> targeting specific mutations will improve patient </a> <a title="EMJ Oncology 6.1 2018 page 63" href="http://viewer.zmags.com/publication/506173e7?page=63"> associated genes). In this study, 333 CUP patient</a> <a title="EMJ Oncology 6.1 2018 page 64" href="http://viewer.zmags.com/publication/506173e7?page=64"> trastuzumab + pertuzumab + chemotherapy </a> <a title="EMJ Oncology 6.1 2018 page 65" href="http://viewer.zmags.com/publication/506173e7?page=65"> Patients whose tumours harbour a mutation th</a> <a title="EMJ Oncology 6.1 2018 page 66" href="http://viewer.zmags.com/publication/506173e7?page=66"> References 1. Krämer A, Losa F. Genomic profi</a> <a title="EMJ Oncology 6.1 2018 page 67" href="http://viewer.zmags.com/publication/506173e7?page=67"> Coming soon. </a> <a title="EMJ Oncology 6.1 2018 page 68" href="http://viewer.zmags.com/publication/506173e7?page=68"> Abstract Reviews Discover the latest research a</a> <a title="EMJ Oncology 6.1 2018 page 69" href="http://viewer.zmags.com/publication/506173e7?page=69"> research support for Genentech/Roche, Merck, GSK,</a> <a title="EMJ Oncology 6.1 2018 page 70" href="http://viewer.zmags.com/publication/506173e7?page=70"> unacceptable toxicity. To be included in th</a> <a title="EMJ Oncology 6.1 2018 page 71" href="http://viewer.zmags.com/publication/506173e7?page=71"> CONCLUSION GSK3359609 alone and in combinatio</a> <a title="EMJ Oncology 6.1 2018 page 72" href="http://viewer.zmags.com/publication/506173e7?page=72"> Dr Gilbert has served on advisory boards for Astr</a> <a title="EMJ Oncology 6.1 2018 page 73" href="http://viewer.zmags.com/publication/506173e7?page=73"> Of the 25 evaluable patients (≥12 weeks of</a> <a title="EMJ Oncology 6.1 2018 page 74" href="http://viewer.zmags.com/publication/506173e7?page=74"> UK (n=34) USA (n=25) Australia (n=31) Italy (n=9)</a> <a title="EMJ Oncology 6.1 2018 page 75" href="http://viewer.zmags.com/publication/506173e7?page=75"> New Immunotherapy Approaches for The Treatment o</a> <a title="EMJ Oncology 6.1 2018 page 76" href="http://viewer.zmags.com/publication/506173e7?page=76"> safety and clinical activity of multiple cancer i</a> <a title="EMJ Oncology 6.1 2018 page 77" href="http://viewer.zmags.com/publication/506173e7?page=77"> patients in good prognostic groups surviving up t</a> <a title="EMJ Oncology 6.1 2018 page 78" href="http://viewer.zmags.com/publication/506173e7?page=78"> The American Society of Clinical Oncology (A</a> <a title="EMJ Oncology 6.1 2018 page 79" href="http://viewer.zmags.com/publication/506173e7?page=79"> Novel Targets and Therapies in T Cell Lymphoma </a> <a title="EMJ Oncology 6.1 2018 page 80" href="http://viewer.zmags.com/publication/506173e7?page=80"> such as the PI3K/Akt/mTOR cascade, which are also</a> <a title="EMJ Oncology 6.1 2018 page 81" href="http://viewer.zmags.com/publication/506173e7?page=81"> T cell lymphoma (16 of whom had ALCL) were treate</a> <a title="EMJ Oncology 6.1 2018 page 82" href="http://viewer.zmags.com/publication/506173e7?page=82"> achieved a partial response, 4 (36%) had stable d</a> <a title="EMJ Oncology 6.1 2018 page 83" href="http://viewer.zmags.com/publication/506173e7?page=83"> PI3K/AKT/mTOR PATHWAY INHIBITION Although not dir</a> <a title="EMJ Oncology 6.1 2018 page 84" href="http://viewer.zmags.com/publication/506173e7?page=84"> NHL xenograft models via downregulation of Myc an</a> <a title="EMJ Oncology 6.1 2018 page 85" href="http://viewer.zmags.com/publication/506173e7?page=85"> agents to randomised trials against standard of c</a> <a title="EMJ Oncology 6.1 2018 page 86" href="http://viewer.zmags.com/publication/506173e7?page=86"> The pivotal PROPEL study,99 a Phase II single- ar</a> <a title="EMJ Oncology 6.1 2018 page 87" href="http://viewer.zmags.com/publication/506173e7?page=87"> With a rapidly evolving understanding of tumour b</a> <a title="EMJ Oncology 6.1 2018 page 88" href="http://viewer.zmags.com/publication/506173e7?page=88"> Pathol. 2010;34(2):178-89. 29. Gatalica Z et al.</a> <a title="EMJ Oncology 6.1 2018 page 89" href="http://viewer.zmags.com/publication/506173e7?page=89"> lymphoproliferative disorders of NK cells and T-c</a> <a title="EMJ Oncology 6.1 2018 page 90" href="http://viewer.zmags.com/publication/506173e7?page=90"> development of T follicular helper cells. Science</a> <a title="EMJ Oncology 6.1 2018 page 91" href="http://viewer.zmags.com/publication/506173e7?page=91"> Recent Advances in the Treatment of Metastatic So</a> <a title="EMJ Oncology 6.1 2018 page 92" href="http://viewer.zmags.com/publication/506173e7?page=92"> from doxorubicin-based regimens, nove</a> <a title="EMJ Oncology 6.1 2018 page 93" href="http://viewer.zmags.com/publication/506173e7?page=93"> Table 2: Targeted agents in soft tissue sarcoma. </a> <a title="EMJ Oncology 6.1 2018 page 94" href="http://viewer.zmags.com/publication/506173e7?page=94"> treatment of patients with STS not amenable to cu</a> <a title="EMJ Oncology 6.1 2018 page 95" href="http://viewer.zmags.com/publication/506173e7?page=95"> There was no difference in RR or OS. Trabectedin </a> <a title="EMJ Oncology 6.1 2018 page 96" href="http://viewer.zmags.com/publication/506173e7?page=96"> Phase III study of pazopanib in patients with adv</a> <a title="EMJ Oncology 6.1 2018 page 97" href="http://viewer.zmags.com/publication/506173e7?page=97"> associated with downregulation of MDM2,61 sug</a> <a title="EMJ Oncology 6.1 2018 page 98" href="http://viewer.zmags.com/publication/506173e7?page=98"> and occasional strong expression of PD-L1, i</a> <a title="EMJ Oncology 6.1 2018 page 99" href="http://viewer.zmags.com/publication/506173e7?page=99"> CONCLUSION STS are a highly heterogeneous gr</a> <a title="EMJ Oncology 6.1 2018 page 100" href="http://viewer.zmags.com/publication/506173e7?page=100"> J Med. 2015;373(5):428-37. 22. Tawbi HA et al. P</a> <a title="EMJ Oncology 6.1 2018 page 101" href="http://viewer.zmags.com/publication/506173e7?page=101"> randomized, double-blind, placebo- controlled and</a> <a title="EMJ Oncology 6.1 2018 page 102" href="http://viewer.zmags.com/publication/506173e7?page=102"> Clinical Issues for Prostate-Specific Antigen S</a> <a title="EMJ Oncology 6.1 2018 page 103" href="http://viewer.zmags.com/publication/506173e7?page=103"> screening test, especially by general practitione</a> <a title="EMJ Oncology 6.1 2018 page 104" href="http://viewer.zmags.com/publication/506173e7?page=104"> Table 2: Characteristics of three major prostate </a> <a title="EMJ Oncology 6.1 2018 page 105" href="http://viewer.zmags.com/publication/506173e7?page=105"> predictive value of DRE for PCa detection h</a> <a title="EMJ Oncology 6.1 2018 page 106" href="http://viewer.zmags.com/publication/506173e7?page=106"> to more aggressive disease being missed at </a> <a title="EMJ Oncology 6.1 2018 page 107" href="http://viewer.zmags.com/publication/506173e7?page=107"> IN PROSTATE CANCER THE VALUE OF FAMILY HISTORY A</a> <a title="EMJ Oncology 6.1 2018 page 108" href="http://viewer.zmags.com/publication/506173e7?page=108"> 15. Gleason DF, Mellinger GT. Prediction </a> <a title="EMJ Oncology 6.1 2018 page 109" href="http://viewer.zmags.com/publication/506173e7?page=109"> Mantle Cell Lymphoma: Are New Therapies </a> <a title="EMJ Oncology 6.1 2018 page 110" href="http://viewer.zmags.com/publication/506173e7?page=110"> and classical MCL.3 The two subtypes have v</a> <a title="EMJ Oncology 6.1 2018 page 111" href="http://viewer.zmags.com/publication/506173e7?page=111"> Phase III trial16 established the superiorit</a> <a title="EMJ Oncology 6.1 2018 page 112" href="http://viewer.zmags.com/publication/506173e7?page=112"> Table 1: Comparison of some of the first-line trea</a> <a title="EMJ Oncology 6.1 2018 page 113" href="http://viewer.zmags.com/publication/506173e7?page=113"> Table 2: Novel agents used in the treatment of ma</a> <a title="EMJ Oncology 6.1 2018 page 114" href="http://viewer.zmags.com/publication/506173e7?page=114"> Ibrutinib is an oral irreversible BTK inhibitor t</a> <a title="EMJ Oncology 6.1 2018 page 115" href="http://viewer.zmags.com/publication/506173e7?page=115"> in an ORR of 71% in relapsed/refractory MCL patie</a> <a title="EMJ Oncology 6.1 2018 page 116" href="http://viewer.zmags.com/publication/506173e7?page=116"> 30% of whom had failed ASCT, while one was a trea</a> <a title="EMJ Oncology 6.1 2018 page 117" href="http://viewer.zmags.com/publication/506173e7?page=117"> Table 3: Ongoing clinical trials in mantle cell l</a> <a title="EMJ Oncology 6.1 2018 page 118" href="http://viewer.zmags.com/publication/506173e7?page=118"> References 1. Dreyling M et al. Newly diagno</a> <a title="EMJ Oncology 6.1 2018 page 119" href="http://viewer.zmags.com/publication/506173e7?page=119"> cell antigen receptors in mantle cell lymphoma. J</a> <a title="EMJ Oncology 6.1 2018 page 120" href="http://viewer.zmags.com/publication/506173e7?page=120"> Events 16TH JANUARY 2019 23RD–25TH JANUARY 2019 </a> <a title="EMJ Oncology 6.1 2018 page 121" href="http://viewer.zmags.com/publication/506173e7?page=121"> 7TH–9TH MARCH 2019 14TH–16TH MARCH 2019 </a> <a title="EMJ Oncology 6.1 2018 page 122" href="http://viewer.zmags.com/publication/506173e7?page=122"> Never miss an update again. J</a>